Abstract: The present invention relates to the treatment of cancer and to the prevention of cancer growth and/or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and/or cancers that develop and/or persist by evading host immune surveillance and/or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

Abstract: The present invention relates to the treatment of cancer and to the prevention of cancer growth and/or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and/or cancers that develop and/or persist by evading host immune surveillance and/or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

Abstract: The present invention relates to the treatment of cancer and to the prevention of cancer growth and/or metastasis. In particular, the invention relates to cellular and acellular vaccines containing C3d, a proteolytic product of complement (C3), and methods of enhancing a host immune response (e.g., a T cell mediated immune response) against cancers using same. Compositions and methods of the invention find use, alone or in conjunction with other cancer therapies, in treating lymphoma and/or cancers that develop and/or persist by evading host immune surveillance and/or responses (e.g., T-cell mediated immune responses). Compositions and methods of the invention find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.

Abstract: This description provides methods and materials related to modulating Toll-like receptor activity. For example, methods and materials for increasing or decreasing the responsiveness of a TLR4 polypeptide are provided.

Abstract: Methods for identifying animals as having reduced body fat and increased bone density are provided herein. Also provided herein are methods for generating animals having reduced body fat and increased bone density. The methods provided herein are based on the effect of TLR4, MD-2, and CD14 activity on body fat and bone density.

Abstract: The invention relates to methods and materials useful for targeting antigenic determinants of mutable pathogens for somatic hypermutation. These methods and materials can be used to induce an immune response against antigenic variants of mutable pathogens.

Abstract: Materials and Methods for modulating TLR activity are described, as well as methods for reducing body fat and increasing bone density.

Abstract: The current document relates to transgenic rodents that have a nucleic acid molecule encoding a hepatocyte mitogen polypeptide.

Abstract: This description provides methods and materials related to modulating Toll-like receptor activity. For example, methods and materials for increasing or decreasing the responsiveness of a TLR4 polypeptide are provided.

Abstract: Methods and materials for enhancing T cell diversity are described. For example, methods that include administering purified populations of B cells or immunoglobulins to subjects in need thereof are provided.

Abstract: The invention relates to methods and materials useful for targeting antigenic determinants of mutable pathogens for somatic hypermutation. These methods and materials can be used to induce an immune response against antigenic variants of mutable pathogens.